Preventive monoclonal antibody from Merck (MRK.US) achieves positive results, used for preventing infant RSV infection.
Merck (MRK.US) announced that the investigational respiratory syncytial virus (RSV) prophylactic monoclonal antibody clesrovimab (MK-1654) has obtained positive results in phase 2b/3 clinical trials.
Acquiring the company for over 1.3 billion US dollars! Merck's (MRK.US) new small-molecule cancer drug has entered phase 3 clinical trials in China.
According to the latest announcement by China's drug clinical trial registration and information disclosure platform, Merck (MRK.US) has initiated a Phase III clinical study for a new oral drug, MK-3543 (bomedemstat), for the treatment of primary thrombocytosis.
Merck & Co To Go Ex-Dividend On September 16th, 2024 With 0.77 USD Dividend Per Share
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
Merck Declares $0.77 Dividend
Express News | Merck & Co Inc - Has Declared a Quarterly Dividend of $0.77 per Share of Company's Common Stock for Q4 of 2024.
Express News | Merck Announces Fourth-Quarter 2024 Dividend
Merck & Co., Inc. (NYSE:MRK) Is Largely Controlled by Institutional Shareholders Who Own 78% of the Company
Merck RSV Therapy Succeeds in Infants in Challenge to Sanofi, Astra
Express News | Merck Says Its Prophylactic Monoclonal Antibody Clesrovimab For Respiratory Syncytial Virus (RSV) Disease Met Its Primary Safety And Efficacy Endpoints
Express News | Merck Reports Results From Phase 2b/3 Trial Of Clesrovimab Antibody Designed To Protect Infants From Respiratory Syncytial Virus Disease; Says Clesrovimab Met All Primary Safety And Efficacy Endpoints
Express News | Merck & Co Inc: Plans to File Data With Global Regulatory Authorities
Express News | Merck & Co Inc - Clesrovimab Met All Primary Safety and Efficacy Endpoints
Express News | Merck Announces Topline Results From Phase 2B/3 Trial of Clesrovimab (Mk-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Kamala Harris' Potential Impact on Health Care Stocks
Here Are Big Pharma's Leading Blockbuster Makers
Merck & Co Options Spot-On: On July 19th, 58,773 Contracts Were Traded, With 355.33K Open Interest
Earnings Preview: What to Expect From Merck & Co.'s Report
BMO Capital Adjusts Price Target on Merck to $150 From $148